One stock that might be an intriguing choice for investors right now is CymaBay Therapeutics, Inc. . This is because this security in the Medical - Generic Drugs space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical - Generic Drugs space as it currently has a Zacks Industry Rank of 15 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.
Meanwhile, CymaBay Therapeutics is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.
CymaBay Therapeutics Inc. Price and Consensus
In fact, over the past month, current quarter estimates have narrowed from a loss of 29 cents per share to a loss of 28 cents per share, while current year estimates have narrowed from a loss of $1.13 per share to a loss of $1.10 per share. This has helped CBAY to earn a Zacks Rank #2 (Buy), further underscoring the company’s solid position. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
So, if you are looking for a decent pick in a strong industry, consider CymaBay Therapeutics. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2020 today >>
Image: Bigstock
Is CymaBay Therapeutics (CBAY) Stock a Solid Choice Right Now?
One stock that might be an intriguing choice for investors right now is CymaBay Therapeutics, Inc. . This is because this security in the Medical - Generic Drugs space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical - Generic Drugs space as it currently has a Zacks Industry Rank of 15 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.
Meanwhile, CymaBay Therapeutics is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.
CymaBay Therapeutics Inc. Price and Consensus
CymaBay Therapeutics Inc. price-consensus-chart | CymaBay Therapeutics Inc. Quote
In fact, over the past month, current quarter estimates have narrowed from a loss of 29 cents per share to a loss of 28 cents per share, while current year estimates have narrowed from a loss of $1.13 per share to a loss of $1.10 per share. This has helped CBAY to earn a Zacks Rank #2 (Buy), further underscoring the company’s solid position. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
So, if you are looking for a decent pick in a strong industry, consider CymaBay Therapeutics. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2020 today >>